关于北美应用利福平治疗非结核感染的最近评论引起了英国医学界的疑问,即:利福平可更广泛的应用,或应保留治疗几种特异的适应症? 利福平于1965年合成,并很快被认识到具有抗结核分支杆菌的活性。也被认为是具有抗革兰氏阳性和革兰氏阴性菌的广谱抗生素。它属于脂溶性物质,能够穿透大多数组织。虽利福平具有这些作用,但医生们担心,使用它后,将出现结核分支杆菌和其他细菌的抗药性,所以很少用于治疗非结核感染。虽然比许多新近 Recent comments on the use of rifampin in North America to treat non-tuberculosis infections have raised questions in the UK medical community about the wider use of rifampicin or the treatment of several specific indications. Rifampin was synthesized in 1965 , And was quickly recognized as having activity against Mycobacterium tuberculosis. It is also considered a broad-spectrum antibiotic with Gram-positive and Gram-negative bacteria. It is a fat-soluble substance that penetrates most tissues. Although rifampicin has these effects, doctors are worried that the use of it will result in resistance to Mycobacterium tuberculosis and other bacteria and are rarely used to treat non-TB infections. Although much newer than many